Innovative drugs achieve record-breaking overseas expansion! Total BD in the opening period exceeds $30 billion; 'R&D efficiency in China' highly regarded.

①The year 2026 began with a significant BD milestone, as the total upfront payments from License-out deals in early 2026 have already exceeded 39% of the total for the entire year of 2025; ②Innovent Bio and Eli Lilly and Co established a collaboration based on a novel molecule outside their existing pipelines, with the upfront payment not subject to additional confirmation conditions; ③CICC stated that China's innovative pharmaceuticals industry has entered the 2.0 era, transitioning from 'imitation through introduction' to 'innovation export'.

cls.cnFeb 17 14:16

Hong Kong Stock Exchange Announcements | Shijiazhuang No. 4 Pharmaceutical Group Annual Profit Exceeds HKD 1 Billion; Shougang Resources' Net Profit for 2025 Declines by More Than 50%

①Shi Si Pharmaceutical Group's annual profit exceeds 1 billion Hong Kong dollars. What is the year-on-year change? ②Shougang Resources' net profit in 2025 declined by more than 50%. What is the scale of its profitability?

cls.cnFeb 16 20:57

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy

MT NewswiresFeb 16 20:26 · Ratings

CSPC Pharma (01093): Long-acting injectable dual biased agonist peptide targeting GLP-1/GIP receptors receives clinical trial approval in the United States.

CSPC Pharma (01093) announced that the GLP-1/GIP receptor dual-biased agonist peptide long-acting injection (SYH2082 Injection) developed by the group has received approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials in the United States.

Zhitong FinanceFeb 16 13:37

CSPC Pharma (01093): Long-acting Ropivacaine Injection (SYH9089 Injection) Receives Clinical Trial Approval in China

CSPC Pharma (01093) announced that the long-acting ropivacaine injection (SYH9089 Injection) developed by the group has been approved by the National Medical Products Administration of the People's Republic of China to commence clinical trials in China.

Zhitong FinanceFeb 16 13:35

Nomura has raised its target price for CSPC Pharmaceutical Group (01093.HK) to HKD 12.04 and reiterated its "Buy" rating.

Nomura issued a research report predicting that CSPC Pharma's (01093.HK) revenue for the fourth quarter of 2025 will increase by 20% year-on-year to RMB 7.6 billion (hereinafter the same), slightly outperforming market expectations of RMB 7.4 billion. The brokerage also expects the group’s finished drug sales to decrease marginally by 1% year-on-year to RMB 5 billion, while collaboration income is projected at RMB 1.1 billion. Furthermore, Nomura anticipates the group’s gross margin to rise by 0.3 percentage points year-on-year to 68.5%, with an operating margin estimated at 19% and net profit forecasted at RMB 1.3 billion. For the fiscal year 2026, the brokerage projects CSPC Pharma’s revenue to grow by 14% year-on-year to RMB 31.2 billion, driven by improvements in the company’s gross margin and operating

AASTOCKSFeb 16 11:20